Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Procaps Group SA (PROC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/11/2025: PROC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.26% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 113.95M USD | Price to earnings Ratio 1.53 | 1Y Target Price 5 |
Price to earnings Ratio 1.53 | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta 0.17 | 52 Weeks Range 0.50 - 3.77 | Updated Date 08/24/2025 |
52 Weeks Range 0.50 - 3.77 | Updated Date 08/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.66 |
Earnings Date
Report Date 2025-09-02 | When - | Estimate - | Actual - |
Profitability
Profit Margin 12.61% | Operating Margin (TTM) 11.13% |
Management Effectiveness
Return on Assets (TTM) 6.28% | Return on Equity (TTM) 37.37% |
Valuation
Trailing PE 1.53 | Forward PE 81.3 | Enterprise Value 2798340843 | Price to Sales(TTM) 0.28 |
Enterprise Value 2798340843 | Price to Sales(TTM) 0.28 | ||
Enterprise Value to Revenue 6.76 | Enterprise Value to EBITDA 22.67 | Shares Outstanding 112824000 | Shares Floating 17150379 |
Shares Outstanding 112824000 | Shares Floating 17150379 | ||
Percent Insiders 83.03 | Percent Institutions 2.93 |
Upturn AI SWOT
Procaps Group SA
Company Overview
History and Background
Procaps Group SA was founded in 1977 in Barranquilla, Colombia. It has grown to become a leading pharmaceutical and healthcare company in Latin America, specializing in softgel technology and pharmaceutical manufacturing.
Core Business Areas
- Softgel Technology: Procaps is a leading softgel manufacturer, providing a wide range of encapsulated pharmaceuticals, nutritional supplements, and over-the-counter products.
- Pharmaceutical Manufacturing: The company offers contract manufacturing services for pharmaceutical companies, including formulation development, manufacturing, and packaging.
- Branded Products: Procaps develops, manufactures, and markets its own portfolio of branded pharmaceutical and nutraceutical products, primarily focused on the Latin American market.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical and healthcare industries. The organizational structure includes functional departments such as R&D, Manufacturing, Marketing, and Sales.
Top Products and Market Share
Key Offerings
- Softgel Pharmaceuticals: Procaps manufactures a wide range of softgel pharmaceuticals, including prescription drugs and over-the-counter medications. Market share data is not publicly available on a product-by-product basis but Procaps is a leading player in Latam softgel manufacturing. Competitors include Catalent (CTLT) and Lonza (LZAGY). Revenue from segment makes up the bulk of company revenue.
- Nutraceutical Softgels: Procaps produces softgel formulations for vitamins, minerals, and dietary supplements. Market share data not available, but they are a significant supplier in the LATAM market. Competitors include Capusgel (acquired by Kohlberg Kravis Roberts (KKR) )and Robinson Pharma.
- Rx Products (Branded): Procaps has a portfolio of Rx brands primarily sold in Latin America including cardiovascular and CNS products. Competitors are local pharmaceutical companies and multinationals such as Novartis (NVS) and Pfizer (PFE). Market share varies by country and product. Revenue varies by country and product and this makes up the rest of the company revenue
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. Trends include increasing demand for generic drugs, growing aging population, and technological advancements in drug delivery systems.
Positioning
Procaps is positioned as a leading softgel manufacturer and provider of pharmaceutical manufacturing services in Latin America. Its competitive advantages include its proprietary softgel technology and its ability to serve both branded and generic pharmaceutical companies.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be over $1 trillion. Procaps is positioned to capture a portion of this market through its focus on softgel technology and manufacturing services. Procaps competes in the Latin American pharmaceutical and nutraceutical market estimated at over $50B
Upturn SWOT Analysis
Strengths
- Leading softgel technology
- Strong presence in Latin America
- Diversified product portfolio
- Contract manufacturing capabilities
- Experienced management team
Weaknesses
- Concentration of revenue in Latin America
- Exposure to currency fluctuations
- Limited brand recognition outside Latin America
- Dependence on raw material suppliers
Opportunities
- Expansion into new geographic markets
- Development of innovative softgel formulations
- Strategic acquisitions
- Increased demand for contract manufacturing services
- Growing nutraceutical market
Threats
- Competition from larger pharmaceutical companies
- Regulatory changes
- Pricing pressures
- Economic downturns
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- CTLT
- NVS
- PFE
Competitive Landscape
Procaps' advantages include its specialized softgel technology and its presence in Latin America. Its disadvantages include its smaller size compared to global pharmaceutical giants and limited brand recognition outside the region.
Major Acquisitions
Grupo Somar
- Year: 2019
- Acquisition Price (USD millions): 46
- Strategic Rationale: Expanded Procaps' portfolio of branded products and strengthened its presence in the Brazilian market. See official fillings for more details
Growth Trajectory and Initiatives
Historical Growth: Procaps has experienced consistent revenue growth over the past several years, driven by its softgel technology and contract manufacturing services.
Future Projections: Analysts project continued revenue growth for Procaps, driven by increased demand for softgel products and expansion into new markets. Expect about 10 to 15 percent growth over next 2 years.
Recent Initiatives: Recent strategic initiatives include expansion of manufacturing capacity, investments in R&D, and acquisitions of complementary businesses.
Summary
Procaps Group SA has a strong position in the Latin American pharmaceutical market. Its softgel technology and contract manufacturing capabilities are key strengths. The company's growth potential is significant, but it faces challenges such as currency fluctuations and competition. The company is in a high growth area with a strong focus but investors need to look out for the financial performance to turn positive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Procaps Group SA Investor Relations
- SEC Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is based on available public information and may be subject to change. Market share data is estimated. Investment decisions should be based on individual research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Procaps Group SA
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-09-30 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 5500 | Website https://www.procapsgroup.com |
Full time employees 5500 | Website https://www.procapsgroup.com | ||
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.